Jazz Pharmaceuticals (JAZZ) Jefferies 2024 Global Healthcare Conference summary

Financial performance and guidance

• Q1 results met expectations, with top-line revenue guidance for the year at $4–4.2 billion and 12% year-over-year growth in key products.

• Commercial investments are being made to sustain growth, especially in XYWAV, Epidiolex, and RYLAZE.

• Oxybate franchise is annualizing at $1.9 billion, close to the 2025 target of $2 billion.

• XYWAV remains the leading product, with significant net patient adds and strong positioning in idiopathic hypersomnia.

• Guidance was reiterated, and market expansion is expected due to increased branded competition.

Research and development pipeline

• Zanidatamab, a bispecific HER2 monoclonal antibody, is highlighted for its strong activity across tumor types.

• BLA for second-line BTC is under FDA review with a PDUFA date of November 29 and MAA completed in Europe.

• Updated BTC data show a median duration of response of 14.9 months and median overall survival over 15 months.

• GEA front-line pivotal trial is ongoing, and a phase III trial in metastatic breast cancer is planned.

• Additional programs in breast cancer and other tumor types are progressing, with external KOL interest.

Strategic vision and business development

• Vision 2025 targets $5 billion in revenue, with $4.5 billion from organic growth and $500 million from corporate development.

• No intention to pursue value-destructive deals; high bar set for business development.

• Recent deals, such as the Zymeworks transaction, were based on asset quality, not just revenue targets.

• Timing of future deals is opportunistic, not tied to specific milestones like HERIZON-GEA data.

• All options for value creation, including potential separation of business units, are considered but no current plans disclosed.